Effect of angiotensin receptor blocker neprilysin inhibitor on renal function in patients with heart failure
-
摘要: 心力衰竭(心衰)患者常伴随肾功能损害,这不仅严重危害了这类患者的身心健康,还使其治疗复杂化。尽管目前已有众多的抗心衰药物,但心衰患者的病死率和并发症发生率仍居高不下,形势相当严峻。首个血管紧张素受体拮抗剂脑啡肽酶抑制剂(ARNI)的出现给心衰患者带来了新的希望,除了可以有效降低心衰患者死亡和住院风险外,ARNI还可以保护心衰患者的肾功能,甚至对同时合并糖尿病、高血压等疾病的心衰患者的肾功能保护也有效。本文就ARNI对心衰患者肾功能的影响进行阐述。
-
关键词:
- 心力衰竭 /
- 血管紧张素受体拮抗剂脑啡肽酶抑制剂 /
- 肾功能
Abstract: Heart failure(HF) is often accompanied by renal impairment, which not only seriously harms the physical and mental health of human beings, but also complicates the treatment. Although there are many anti-HF drugs, the mortality and complication incidence of HF are still high, and the situation is quite grim. The emergence of angiotensin receptor blocker neprilysin inhibitor(ARNI) brings new hope to HF patients. In addition to effectively reducing the risk of death and hospitalization of HF patients, ARNI can also protect the renal function, even for HF patients with diabetes, hypertension, and other diseases. This article will review the effect of ARNI on renal function in patients with HF. -
-
[1] Smith GL,Lichtman JH,Bracken MB,et al.Renal impairment and outcomes in heart failure:systematic review and meta-analysis[J].J Am Coll Cardiol,2006,47(10):1987-1996.
[2] Jackson CE,Solomon SD,Gerstein HC,et al.Albuminuria in chronic heart failure:prevalence and prognostic importance[J].Lancet,2009,374(9689):543-550.
[3] McMurray JJ,Packer M,Desai AS,et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med,2014,371(11):993-1004.
[4] Clark H,Krum H,Hopper I.Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction[J].Eur J Heart Fail,2014,16(1):41-48.
[5] Yancy CW,Jessup M,Bozkurt B,et al.2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J].J Card Fail,2017,23(8):628-651.
[6] Chang HY,Feng AN,Fong MC,et al.Sacubitril/valsartan in heart failure with reduced ejection fraction patients:Real world experience on advanced chronic kidney disease,hypotension,and dose escalation[J].J Cardiol,2019,74(4):372-380.
[7] Solomon SD,Zile M,Pieske B,et al.The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction:a phase 2 double-blind randomised controlled trial[J].Lancet,2012,380(9851):1387-1395.
[8] Voors AA,Gori M,Liu LC,et al.Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction[J].Eur J Heart Fail,2015,17(5):510-517.
[9] Ito S,Satoh M,Tamaki Y,et al.Safety and efficacy of LCZ696,a first-in-class angiotensin receptor neprilysin inhibitor,in Japanese patients with hypertension and renal dysfunction[J].Hypertens Res,2015,38(4):269-275.
[10] Damman K,Gori M,Claggett B,et al.Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure[J].JACC Heart Fail,2018,6(6):489-498.
[11] Packer M,Claggett B,Lefkowitz MP,et al.Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system:a secondary analysis of the PARADIGM-HF trial[J].Lancet Diabetes Endocrinol,2018,6(7):547-554.
[12] Haynes R,Judge PK,Staplin N,et al.Effects of Sacubitril/Valsartan versus irbesartan in patients with chronic kidney disease[J].Circulation,2018,138(15):1505-1514.
[13] Spannella F,Marini M,Giulietti F,et al.Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction:a real life 1-year follow-up study[J].Intern Emerg Med,2019,14(8):1287-1297.
[14] Solomon SD,McMurray J,Anand IS,et al.Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J].N Engl J Med,2019,381(17):1609-1620.
[15] Velazquez EJ,Morrow DA,DeVore AD,et al.Angiotensin-neprilysin inhibition in acute decompensated heart failure[J].N Engl J Med,2019,380(6):539-548.
[16] Lee S,Oh J,Kim H,et al.Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease[J].ESC Heart Fail,2020,7(3):1125-1129.
[17] Damman K,Perez AC,Anand IS,et al.Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment[J].J Am Coll Cardiol,2014,64(11):1106-1113.
[18] Uijl E,'t Hart DC,Roksnoer L,et al.Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury[J].J Hypertens,2020,38(4):755-764.
[19] Habibi J,Aroor AR,Das NA,et al.The combination of a neprilysin inhibitor(sacubitril)and angiotensin-II receptor blocker(valsartan)attenuates glomerular and tubular injury in the Zucker Obese rat[J].Cardiovasc Diabetol,2019,18(1):40.
[20] Quiroga B,de Santos A,Sapiencia D,et al.Sacubitril/valsartan in chronic kidney disease,the nephrologist point of view[J].Nefrologia,2019,39(6):646-652.
[21] Ayalasomayajula S,Langenickel T,Pal P,et al.Erratum to:clinical pharmacokinetics of Sacubitril/Valsartan(LCZ696):a novel angiotensin receptor-neprilysin inhibitor[J].Clin Pharmacokinet,2018,57(1):105-123.
[22] Suematsu Y,Jing W,Nunes A,et al.LCZ696(Sacubitril/Valsartan),an angiotensin-receptor neprilysin inhibitor,attenuates cardiac hypertrophy,fibrosis,and vasculopathy in a rat model of chronic kidney disease[J].J Card Fail,2018,24(4):266-275.
[23] Rubattu S,Cotugno M,Forte M,et al.Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs.angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat[J].J Hypertens,2018,36(9):1902-1914.
[24] Okamoto R,Ali Y,Hashizume R,et al.BNP as a major player in the heart-kidney connection[J].Int J Mol Sci,2019,20(14).
[25] Wong PC,Guo J,Zhang A.The renal and cardiovascular effects of natriuretic peptides[J].Adv Physiol Educ,2017,41(2):179-185.
[26] Volpe M,Carnovali M,Mastromarino V.The natriuretic peptides system in the pathophysiology of heart failure:from molecular basis to treatment[J].Clin Sci(Lond),2016,130(2):57-77.
[27] 赵跃华,王占启,石向欣,等.沙库巴曲缬沙坦(LCZ696)治疗心力衰竭的研究进展[J].临床心血管病杂志,2019,35(6):491-494.
[28] Ayalasomayajula SP,Langenickel TH,Jordaan P,et al.Effect of renal function on the pharmacokinetics of LCZ696(sacubitril/valsartan),an angiotensin receptor neprilysin inhibitor[J].Eur J Clin Pharmacol,2016,72(9):1065-1073.
[29] Jhund PS,Fu M,Bayram E,et al.Efficacy and safety of LCZ696(sacubitril-valsartan)according to age:insights from PARADIGM-HF[J].Eur Heart J,2015,36(38):2576-2584.
[30] Ruilope LM,Dukat A,Bohm M,et al.Blood-pressure reduction with LCZ696,a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin:a randomised,double-blind,placebo-controlled,active comparator study[J].Lancet,2010,375(9722):1255-1266.
[31] McMurray JJV,Jackson AM,Lam CSP,et al.Effects of Sacubitril-Valsartan versus Valsartan in women compared with men with heart failure and preserved ejection fraction:insights from PARAGON-HF[J].Circulation,2020,141(5):338-351.
[32] Kristensen SL,Martinez F,Jhund PS,et al.Geographic variations in the PARADIGM-HF heart failure trial[J].Eur Heart J,2016,37(41):3167-3174.
[33] Tan NY,Sangaralingham LR,Sangaralingham SJ,et al.Comparative effectiveness of Sacubitril-Valsartan versus ACE/ARB therapy in heart failure with reduced ejection fraction[J].JACC Heart Fail,2020,8(1):43-54.
-
计量
- 文章访问数: 481
- PDF下载数: 181
- 施引文献: 0
下载: